Conference Coverage

Certolizumab Eased Skin and Joint Symptoms in PsA


 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Mease reported financial relation ships with UCB, which markets certolizumab. In addition, as a clinical trialist he has financial relationships with numerous other pharmaceutical companies that are interested in rheumatologic diseases.

Pages

Recommended Reading

High-Dose Ustekinumab Stomps Out Palmoplantar Psoriasis
MDedge Rheumatology
Anti-TNF Treatment Linked to Reduced CV Risk
MDedge Rheumatology
'Near Remission' May Predict 3-Year Outcome in Early RA
MDedge Rheumatology
EULAR Takes on Systemic Steroids' Risks
MDedge Rheumatology
RA Diagnosed Earlier Using 2010 Classification Criteria
MDedge Rheumatology
Getting RA into Remission Saves Lives
MDedge Rheumatology
RABBIT Score for Infection Risk Validated in Second Population
MDedge Rheumatology
RA Patient Feedback Suggests Criteria Fall Short
MDedge Rheumatology
Weight Contributes to Anti-TNF Response in PsA
MDedge Rheumatology
NSAIDs Retard Bone Formation In Ankylosing Spondylitis
MDedge Rheumatology